Related Experiment Video
Updated: Jun 10, 2025
07:13
Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity
Published on: January 6, 2015
10.6K
Alpha 1 antitrypsin augmentation for alpha 1 antitrypsin deficiency associated lung disease
Patrick Glaister1, Nichola Hindle Robinson1, Amy Ward1
1Library and Knowledge Service, East Lancashire Hospitals NHS Trust, Blackburn, UK.
The Cochrane Database of Systematic Reviews
|October 16, 2024
Summary
Alpha 1 antitrypsin augmentation therapy may benefit individuals with alpha 1 antitrypsin deficiency. This review assesses its impact on respiratory disease outcomes.
Area of Science:
- Pulmonology
- Genetics
- Pharmacology
Background:
- Alpha 1 antitrypsin deficiency is a genetic disorder increasing risk of lung disease.
- Augmentation therapy aims to increase serum alpha 1 antitrypsin levels.
Purpose of the Study:
- To evaluate the efficacy of alpha 1 antitrypsin augmentation therapy.
- To assess the therapy's effects on respiratory disease in patients with alpha 1 antitrypsin deficiency.
Main Methods:
- This is a protocol for a Cochrane Review.
- Systematic review methodology will be employed.
Main Results:
- Data on respiratory disease progression and exacerbations will be analyzed.
- Quality of life and mortality data will also be considered.
Conclusions:
- Findings will inform clinical practice regarding alpha 1 antitrypsin augmentation therapy.
- Evidence will guide treatment decisions for individuals with this deficiency.
Related Concept Videos
01:24Cystic Fibrosis: Management
144
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
144
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
180
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
180
01:29Acute Respiratory Failure-V
124
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
124
01:19Antiasthma Drugs: Leukotriene Modifiers
249
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
249
01:26COPD: Management Using Bronchodilators and Corticosteroids
184
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
184
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K